https://classic.clinicaltrials.gov/ct2/show/NCT05643729
Phase 2
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
https://clinicaltrials.gov/ct2/show/NCT04072887?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients Condition : Pulmonary Disease, Chronic Obstructive Interventions : Drug: QBW251; Drug: Placebo Sponsor : Novartis Pharmaceuticals Not yet recruiting NCT04072887 Wed, 28 Aug 2019 12:00:00 EDT
A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease
https://clinicaltrials.gov/ct2/show/NCT04091360?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease Condition : COPD Interventions : Drug: Ensifentrine 100mcg; Drug: Ensifentrine 300mcg; Drug: Ensifentrine 1000mcg; Drug: Ensifentrine 3000mcg; Drug: Ensifentrine 6000mcg; Drug: Placebos Sponsors : Verona Pharma plc; Iqvia Pty Ltd Recruiting NCT04091360 Mon, 16 Sep 2019 12:00:00 EDT
The Use of Benralizumab, an Interleukin-5 Receptor-α Monoclonal Antibody as Treatment of Acute Exacerbations of Airways Disease
https://clinicaltrials.gov/ct2/show/NCT04098718?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Acute Exacerbations Treated With BenRAlizumab (The ABRA Study) Conditions : Asthma; COPD Interventions : Drug: Benralizumab; Drug: Prednisolone Sponsor : University of Oxford Not yet recruiting NCT04098718 Mon, 23 Sep 2019 12:00:00 EDT
Study to evaluate the impact of inhaled PT003 in moderate to severe COPD patients
https://clinicaltrials.gov/ct2/show/NCT04087590?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Impact of Inhaled PT003 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient Condition : Copd Intervention : Drug: Formoterol-glycopyrronium co suspension (PT003) Sponsors : University Hospital, Lille; AstraZeneca Not yet recruiting NCT04087590 Thu, 12 Sep 2019 12:00:00 EDT
The Effect of FP-025, a MMP-12 Inhibitor, on Airway Responses and Airway Inflammation
https://clinicaltrials.gov/ct2/show/NCT03858686?type=Intr&cond=COPD&phase=01234&lupd_s=02%2F15%2F2019&lupd_d=14&sort=nwst The Effect of FP-025, a MMP-12 Inhibitor, on Allergen-induced Airway Responses and Airway Inflammation in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma Condition : Asthma, COPD Interventions : Drug: FP-025 capsules; Drug: Placebo FP-025 capsules Sponsor : Foresee Pharmaceuticals Co., Ltd. Recruiting NCT03858686 Fri, 01 Mar 2019 12:00:00 EST
The Effects of RPL554 in Addition to Tiotropium in COPD Patients [Completed]
https://clinicaltrials.gov/ct2/show/NCT03028142?type=Intr https://clinicaltrials.gov/ct2/show/NCT03028142?type=Intr&cond=COPD&phase=01234&lupd_s=01%2F09%2F2019&lupd_d=14&sort=nwst The Effects of RPL554 in Addition to Tiotropium in COPD Patients Condition : Chronic Obstructive Pulmonary Disease Moderate Interventions : Drug: 1.5 mg RPL554 plus tiotropium; Drug: 6 mg RPL554 plus tiotropium; Drug: Placebo plus tiotropium Sponsor : Verona Pharma plc Completed NCT03028142 Mon, 23 Jan 2017 12:00:00 EST
A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia
https://clinicaltrials.gov/ct2/show/NCT03810183?type=Intr&cond=COPD&phase=01234&lupd_s=01%2F04%2F2019&lupd_d=14&sort=nwst A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia Condition : COPD Interventions : Drug: QAW039; Drug: Placebo Sponsor : Novartis Pharmaceuticals Not yet recruiting NCT03810183 Fri, 18 Jan 2019 12:00:00 EST
A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza
https://clinicaltrials.gov/ct2/show/NCT03570359?type=Intr&cond=COPD&phase=01234&lupd_s=12%2F17%2F2018&lupd_d=14&sort=nwst A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza Condition : Chronic Obstructive Pulmonary Disease (COPD) Interventions : Drug: Interferon Beta-1A; Other: Placebo Sponsor : Synairgen Research Ltd. Recruiting NCT03570359 Wed, 27 Jun 2018 12:00:00 EDT
Alvelestat (MPH996) for the Treatment of ALpha-1 ANTitrypsin Deficiency
https://clinicaltrials.gov/ct2/show/NCT03679598?type=Intr&cond=COPD&phase=01234&lupd_s=12%2F13%2F2018&lupd_d=14&sort=nwst Alvelestat (MPH996) for the Treatment of ALpha-1 ANTitrypsin Deficiency Conditions : Alpha-1 Antitrypsin Deficiency (AATD); Pi*ZZ, Pi*SZ, or Pi*Null Phenotype; Emphysema or COPD Interventions : Drug: Alvelestat (MPH996); Other: Placebo Sponsors : University of Alabama at Birmingham; National Institutes of Health (NIH); Mereo BioPharma Not yet recruiting NCT03679598 Thu, 20 Sep 2018 12:00:00 EDT >>> updated dec 18, 2018
A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases
https://clinicaltrials.gov/ct2/show/NCT03645434?type=Intr&cond=COPD&phase=01234&lupd_s=10%2F25%2F2018&lupd_d=14&sort=nwst A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases. Condition : Chronic Obstructive Pulmonary Disease Interventions : Drug: AZD8871; Drug: Anoro® Ellipta® Sponsors : AstraZeneca; Parexel Recruiting NCT03645434 Fri, 24 Aug 2018 12:00:00 EDT
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo
https://clinicaltrials.gov/ct2/show/NCT03636347?type=Intr&cond=COPD&phase=01234&lupd_s=11%2F01%2F2018&lupd_d=14&sort=nwst A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. Conditions : Alpha 1-Antitrypsin Deficiency; Emphysema; COPD Interventions : Drug: Placebo Oral Tablet; Drug: Alvelestat oral tablet – dose 1; Drug: Alvelestat oral tablet – dose 2 Sponsors : Mereo BioPharma; Syneos Health Recruiting NCT03636347 Fri, 17 Aug 2018 12:00:00 EDT
Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders
https://clinicaltrials.gov/ct2/show/NCT02946658?type=Intr&cond=COPD&phase=01234&lupd_s=10%2F25%2F2018&lupd_d=14&sort=nwst Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders Condition : Lung Disease Interventions : Procedure: lipoaspiration; Procedure: ADcSVF; Procedure: Normal Saline IV Sponsors : Healeon Medical Inc; Terry, Glenn C., M.D. Recruiting NCT02946658 Thu, 27 Oct 2016 12:00:00 EDT
A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients
https://clinicaltrials.gov/ct2/show/NCT02635945?type=Intr&cond=COPD&phase=01234&lupd_s=10%2F23%2F2018&lupd_d=14&sort=nwst A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients. Condition : Asthma Interventions : Drug: PBF-680; Drug: Placebo Sponsors : Palobiofarma SL; Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau; […]
